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Latent human cytomegalovirus (HCMV) infection is characterized by limited gene expres-
sion, making latent HCMV infections refractory to current treatments targeting viral repli-
cation. However, reactivation of latent HCMV in immunosuppressed solid organ and stem
cell transplant patients often results in morbidity. Here, we report the killing of latently
infected cells via a virus-specific nanobody (VUN100bv) that partially inhibits signaling of the
viral receptor US28. VUN100bv reactivates immediate early gene expression in latently
infected cells without inducing virus production. This allows recognition and killing of latently
infected monocytes by autologous cytotoxic T lymphocytes from HCMV-seropositive indi-
viduals, which could serve as a therapy to reduce the HCMV latent reservoir of transplant
patients.
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Latent reservoirs of viral pathogens are significant barriers tothe eradication of these viruses from their hosts1–3. Duringlatency, human herpesviruses and retroviruses maintain
their viral genomes in the absence of infectious virus particle
production, often with limited viral gene expression4. As such,
latent infections are refractory to treatment with typical antivirals
that target replication of the virus2. Furthermore, the low number
of latently infected cells and the relatively low levels of viral gene
expression during latency reduces the levels of viral antigens that
would otherwise be readily detectable by the host immune
system3. Reactivation from latency results in the dissemination
and reseeding of the virus. In the case of the ubiquitous beta-
herpesvirus human cytomegalovirus (HCMV), such sporadic
reactivation events are well controlled by a combination of cel-
lular and humoral immunity3. In particular, cytotoxic T lym-
phocytes (CTLs) against the HCMV immediate-early (IE)
antigens are present at high frequency in HCMV-seropositive
individuals5. In immunocompromised or immunosuppressed
individuals, this control of reactivation is lost, and for both solid
organ and stem cell transplant patients, HCMV reactivation
frequently results in a disseminated viral infection that is a major
cause of transplant rejection and mortality3.
Targeting the latent viral reservoir in graft donors and reci-
pients could lower the incidence and severity of HCMV-
associated disease in transplant patients3. Latently infected
CD34+ hematopoietic progenitor cells and their derived CD14+
monocytes suppress IE gene expression via the remodeling of
chromatin structure and multiple repressive transcription factors
at the viral major immediate-early promoter/enhancer region
(MIEP)6. By using pan-specific histone deacetylase (HDAC)
inhibitors, we previously showed that transient activation of lytic
IE gene expression in latently infected monocytes results in CTL-
mediated killing of infected cells7. However, we wished to develop
a virus-specific molecule that would limit off-target effects but,
similarly, induce IE gene expression for use as a shock-and-kill
therapeutic.
The viral protein US28, a chemokine receptor with high
homology to human chemokine receptors, is expressed during
HCMV latency8–10. Importantly, a number of reports using
particular models of HCMV latency have shown that
US28 signaling is essential for the establishment and maintenance
of HCMV latency, which is due, at least in part, to US28-
mediated repression of the major IE promoter8,11–13. Previously,
a monovalent, antagonistic nanobody targeting US28 was
generated14.
Here, we show the partial reactivation and CTL-mediated
killing of latently infected cells via a bivalent nanobody,
VUN100bv, derived from this previously described monovalent
nanobody. VUN100bv binds and partially inhibits signaling of
the viral protein US28. We show that partial inverse agonistic
activity of VUN100bv results in transient activation of the MIEP
and subsequent IE gene expression during latency, but no full
virus reactivation. Consequently, VUN100bv treatment drives
recognition and killing of latently infected monocytes by CTLs,
and demonstrates the efficacy of VUN100bv for lowering latent
viral loads in ex vivo experimentally infected peripheral blood
mononuclear cells (PBMCs).
Results
Generation of a partial inverse agonistic US28-targeting
nanobody. The virally encoded chemokine receptor US28 is
absolutely essential for HCMV latency in a number of myeloid
cell models of HCMV latency8,11,12. Consistent with this, inhi-
bition of US28 using the small-molecule US28 inhibitor VUF2274
results in untimely reactivation of the full viral lytic transcription
program and production of new infectious viral particles12.
However, VUF2274 also shows substantial toxicity and is known
to inhibit general CCR1 signaling12,15. Consequently, we rea-
soned that new, highly specific reagents that target and inhibit
US28 would be needed for any safe shock-and-kill strategy.
To this end, we developed a new partial inverse agonistic
US28-targeting nanobody in the hope that it would inhibit US28
function and efficiently induce IE gene expression for subsequent
targeting by host IE-specific CTLs. Nanobodies targeting the
extracellular domains of several chemokine receptors are
antagonistic as monovalent formats and display inverse agonistic
properties as bivalent nanobodies16,17. We, therefore, developed a
bivalent format of our existing nanobody (VUN100), which we
termed VUN100bv14. The monovalent nanobody VUN100
displaces US28 endogenous ligands and binds the extracellular
domains of US28 with high affinity14. VUN100bv was created by
fusing two VUN100 molecules using a 30GS linker. This fusion of
two VUN100 molecules showed an approximately 10-fold
increase in binding affinity compared to the monovalent
VUN100 (0.2 nM ± 0.1 vs 2 nM ± 1) (Fig. 1a). Similarly,
VUN100bv displaced 125I-labeled CX3CL1, a known US28
ligand, with approximately 10-fold higher pKi compared to
monovalent VUN100 (9.4 ± 0.4 vs 8.1 ± 0.1) (Fig. 1b). Next, we
tested the functional effect of VUN100bv on NFAT (Nuclear
Factor of Activated T cells) signaling, which is induced by US28
wildtype (WT) receptor and several US28 mutants in
HEK293T cells (Fig. 1c)18. These mutants included US28 ΔN
(2–22) mutant (lacking the entire N-terminus, unable to bind
US28 ligands but signals in a constitutive manner), US28 Y16F
mutant (unable to bind chemokines but signals in a constitutive
manner), and a US28 R129A mutant (US28R3.50A, unable to
couple to G proteins and signal in a constitutive manner). To
determine the functional effects of the US28 nanobodies on US28
activity, HEK293T cells were co-transfected with a vector
expressing HA-tagged US28 (mutants) and a vector containing
the luciferase gene under the control of an NFAT-promoter. We
confirmed that the expression levels of the different US28
constructs were similar to ensure that the observed differences in
US28-mediated NFAT activity are solely due to differences
induced by the US28 nanobodies (Supplementary Fig. 1).
Consistent with previous studies, we found that US28-mediated
NFAT activation was dependent on constitutive signaling as
NFAT activation was observed for all different US28 constructs
except for the US28 R129A G protein uncoupled mutant18. Then,
we analyzed the effect of VUN100bv on US28 constitutive
activity. When added to cells expressing US28 WT or US28 Y16F
mutant receptor, VUN100bv inhibited US28 constitutive activity
by 44.9 (±0.9)% and 46.7 (±0.6)%, respectively. As predicted, this
inhibitory effect of VUN100bv was not seen for the US28 ΔN
(2–22) mutant, since binding of VUN100(bv) to US28 depends
on the N-terminus14. No significant effects on US28-mediated
NFAT activity were observed for the monovalent VUN100 or a
non-targeting nanobody. We also confirmed that a vast excess of
the monovalent VUN100 nanobody could not recapitulate the
inverse agonist properties of VUN100bv. Even at a 10-fold higher
concentration (1 µM) of monovalent VUN100, corresponding to
400-fold times its Kd value, no inhibition of constitutive signaling
of US28 to NFAT was observed (Supplementary Fig. 2). This
strongly indicates that VUN100 has no inverse agonistic activity.
Taken together, our results show that VUN100bv acts as an
antagonist by competing for binding of CX3CL1 to US28 and as a
partial inverse agonist by inhibiting the constitutive activity of
US28.
Next, we evaluated the binding to US28 and inverse agonistic
activity of VUN100bv in the monocytic THP-1 cell line, an
established model for HCMV latency19. Both VUN100 and
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Fig. 1 VUN100bv binds and inhibits US28 signaling. a ELISA binding of monovalent VUN100 and bivalent VUN100bv to membrane extracts of US28-
expressing HEK293T cells. Representative figure of three independent experiments. b Displacement of 125I-CX3CL1 from US28-expressing membranes by
unlabeled ligand or the nanobodies VUN100 and VUN100bv. Representative figure of three independent experiments. c Effect of nanobodies on US28-
mediated NFAT (nuclear factor of activated T cells) activation. HEK293T cells expressing either NFAT-luciferase reporter only (Mock) or NFAT-luciferase
reporter together with US28 wildtype receptor (WT), US28 Y16F mutant (Y16F), US28 ΔN (2–22) mutant (ΔN (2–22)) or US28 R129A mutant (R129A).
Cells were untreated (untr) or treated with a non-targeting nanobody (NT Nb), VUN100, or VUN100bv for 24 h prior to luminescence measurement. Data
were normalized to the untreated WT samples. Representative figure of three independent experiments. d Immunofluorescence microscopy of nanobody
binding to US28-expressing THP-1 cells. US28 was detected using a polyclonal rabbit-anti-US28 antibody (US28 mAb). Cells were incubated without
nanobody (No Nb), an NT Nb, VUN100, or VUN100bv. Bound nanobody was detected using the Myc-tag present on the nanobodies and an anti-Myc
antibody (Nb). Representative figure of three independent experiments. e Western blot detection for total IFI16 levels of lysates of untreated THP-1 mock
transduced cells (THP-1 Mock) or US28-expressing THP-1 cells (THP-1 US28 WT). THP-1 US28 WT cells were untreated (Untr) or treated with NT Nb,
VUN100, or VUN100bv for 48 h. IFI16 protein levels were determined and normalized to actin protein levels. Relative IFI16 protein levels were normalized
to untreated THP-1 mock cell lysates. n= 3 independent experiments from three independent biological replicates. All data are plotted as mean ± S.D. For
all data, except for Fig. 1c, statistical analyses were performed using an unpaired two-tailed t test. For Fig. 1c, statistical significance was determined using
the Holm–Sidak method (two-sided with alpha= 0.05). Source data are provided as a Source Data file.
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VUN100bv bound to US28-expressing THP-1 cells, unlike the
non-targeting nanobody (Fig. 1d). In addition, none of the three
nanobodies bound to mock transduced THP-1 cells, which do not
express US28, indicating that these nanobodies are specific to our
target (Supplementary Fig. 3). We then assessed the effect of the
anti-US28 nanobodies on US28-mediated signaling in THP-1
cells by assessing IFI16 protein levels (Fig. 1e). IFI16 is
downregulated by WT US28, but not the US28 R129A G protein
uncoupled mutant, to support the repression of the MIEP20.
VUN100bv treatment of US28-expressing THP-1 cells resulted in
full restoration of total IFI16 protein levels while this was not seen
for the non-targeting nanobody. Interestingly, VUN100 treat-
ment also partially restored IFI16 protein levels. Altogether, our
results show that, while both VUN100 and VUN100bv can bind
to US28, only VUN100bv is able to consistently inhibit
constitutive US28 signaling in both HEK293T cells and mono-
cytic THP-1 cells.
US28 nanobodies induce IE expression in infected CD14+
monocytes. Because repression of HCMV MIEP is a downstream
consequence of US28 signaling in latently infected myeloid cells,
we hypothesized that US28 inhibition by the inverse agonist
VUN100bv might drive the inability to establish or maintain
latency via the (re)activation of viral IE expression from the MIEP
in otherwise latently infected cells. Consequently, we determined
the effect of the US28 nanobodies on the establishment of latency
in infected monocytes. Primary CD14+ monocytes were isolated,
infected with HCMV for 2 h, and treated afterward with nano-
bodies. At two and 6 days post infection, IE expression was
assessed (Fig. 2a, b and Supplementary Fig. 4). As a positive
control for induction of lytic viral gene expression in these assays,
we treated monocytes with the phorbol ester PMA (phorbol
myristate acetate), which induces differentiation of monocytes to
a macrophage-like phenotype and is known to result in reacti-
vation of HCMV lytic infection within 24–48h of treatment
rather than the 5–7 days needed for induction of reactivation by
differentiation of monocytes to monocyte-derived mature den-
dritic cells (mDCs) by GM-CSF/lipopolysaccharide (LPS)13,21. As
expected, PMA treatment resulted in an increase in IE expression.
VUN100bv treatment also resulted in an increase in IE-
expressing monocytes compared with untreated or non-
targeting nanobody-treated monocytes (Fig. 2a, b). Interestingly,
we saw a small but significant increase in IE expression with the
antagonistic monovalent VUN100 in three out of four donors
(Fig. 2a, b, Supplementary Fig. 4 and Supplementary Table 1). To
ensure no bias in quantifying IE-positive cells, IE expression at 2
and 6 days post infection was also quantified using an automated
plate reader (Supplementary Fig. 5). Similar results were obtained
using automated quantification validating the results obtained via
manual counting. To quantify full viral reactivation and sub-
sequent virus production, latently infected cells were co-cultured
with indicator fibroblasts, a cell type permissive for lytic infection,
after nanobody treatment. We then quantified the formation of
IE2-eYFP-positive infectious foci, a consequence of viral infection
of the indicator fibroblasts, to determine the level of virus pro-
duction. Importantly, none of the nanobodies, including
VUN100bv, resulted in any significant IE focus formation
(Fig. 2c). In contrast, the production of infectious virus from
latently infected monocytes was induced with PMA treatment.
To ensure that VUN100bv also reverses latency and not only
prevents the establishment of latency mediated by US28, we
performed similar experiments but added the nanobodies or
PMA after the establishment of latency at 6 days post infection, a
time frame that routinely establishes latent infection in primary
monocytes. Six days post infection and before treatment, no
significant differences in IE expression between the different wells
were observed (Supplementary Fig. 6). Again, VUN100bv
treatment resulted in a significant upregulation of IE expression
compared with the untreated or non-targeting nanobody-treated
monocytes (Fig. 2d). Treatment with monovalent VUN100 also
resulted in a very small but significant upregulation of IE
expression. Importantly, no production of infectious viral
particles was observed from the untreated or nanobody-treated
monocytes upon co-culturing with fibroblasts for eight days
(Fig. 2F). In contrast, co-culturing of PMA-treated latently
infected monocytes with fibroblasts resulted in a significant
upregulation of IE2-eYFP-positive infectious foci formation.
Moreover, to ensure that the effect of VUN100bv is US28-
specific, we performed the same experiments with Titan WT and
Titan ΔUS28 virus (Supplementary Fig. 7). Also in this setting,
using the Titan WT virus, we noticed a significant upregulation of
IE expression upon VUN100bv or PMA treatment of latently
infected cells compared to the untreated or non-targeting
nanobody-treated cells. In contrast, using the Titan-ΔUS28 virus,
increase in IE expression was observed, caused by the lack of
US28 expression by this virus12. However, IE expression could be
further increased by PMA treatment. Treatment of the Titan-
ΔUS28-infected CD14+ monocytes with the non-targeting
nanobody resulted in a small, but not significant, increase of IE
expression compared to the untreated cells. However, most
importantly, VUN100bv treatment did not result in higher IE
expression compared with the non-targeting nanobody, indicat-
ing that the effect of VUN100bv is US28-specific. Taken together,
these results indicate that VUN100bv treatment results in only a
partial reactivation of the viral lytic transcription program in a
US28-specific manner in latently infected CD14+ monocytes.
While reactivating the monocytes at the level of IE expression, the
nanobody treatments do not result in reactivation of full virus
production.
To analyze the extent of reactivated lytic gene expression
induced by VUN100bv in more detail, we assessed viral gene
expression in latently infected monocytes treated with nanobo-
dies. To do this, we also used monocytes treated with PMA,
which induces myeloid differentiation and permits full lytic
infection. At 6 days post infection, RNA was isolated and gene
expression of different markers was tested by RT-qPCR (Fig. 3).
As expected, PMA treatment of infected monocytes resulted in
increased levels of transcripts from the major IE IE72 gene, the
early UL44 gene, the late UL32 gene, and the US11 immune
evasion gene (Fig. 3). Moreover, we noticed that the addition of
the non-targeting nanobody resulted in a small induction of gene
expression of IE72, UL44, and US11, which could be owing to a
non-specific effect of the non-targeting nanobody, residual
contaminants, or simply manipulation of the cells.
Consistent with Fig. 2, VUN100bv treatment of infected CD14+
monocytes resulted in increased levels of the major IE IE72
transcript, compared to the non-targeting nanobody treatment
(Fig. 3a). Although VUN100bv treatment resulted in a significant
upregulation of major IE IE72 transcript levels compared with the
untreated samples, this was not the case for the non-targeting
nanobody. In contrast, expression of the early UL44 gene was only
slightly increased by VUN100bv compared with non-targeting
nanobody or VUN100 treatment, suggesting that viral DNA
replication would not be optimal in these cells (Fig. 3b).
Importantly, VUN100bv treatment did not result in UL32 gene
expression (Fig. 3c), which encodes the true late virion-associated
protein pp150. This is consistent with our inability to detect
infectious virus production in these cells (see Fig. 2).
Finally, we were minded that any shock-and-kill strategy could
be thwarted by the expression of viral immune evasins. We
therefore also assessed the effect of nanobody treatment on the
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expression of the immune evasion gene US11 (Fig. 3d). In
contrast to PMA, the slight increase of US11 gene expression was
discernibly and significantly lower for the nanobodies compared
to differentiation-induced reactivation. Taken together, these
results confirm that VUN100bv treatment results in an increase
of IE expression and only low levels of other viral gene products.
HCMV-infected CD14+ monocytes are targets for T cells upon
VUN100bv treatment. Since HCMV-positive donors have a high
frequency of IE-specific CTLs that likely limit virus dissemination
from sporadic reactivation events5, we evaluated whether the
VUN100bv-induced partial reactivation of infected CD14+
monocytes would allow clearance of these cells by HCMV-specific

























































































Fig. 2 VUN100bv induces immediate-early expression but no full viral reactivation. a CD14+ monocytes were isolated, infected with HCMV IE2-eYFP,
and were left untreated or treated with a non-targeting nanobody, VUN100 or VUN100bv. Two days post infection, cells were fixed and stained for
immediate-early (IE) expression. b CD14+ monocytes were isolated, infected with HCMV IE2-eYFP, and were left untreated (Untr) or treated with a non-
targeting nanobody (NT Nb), VUN100, or VUN100bv. As a positive control, CD14+ monocytes were pre-treated with 20 ng/ml PMA before infection
(PMA). IE-positive nuclei were counted 6 days post infection. c Six days post infection, untreated (untr), nanobody-treated monocytes (NT Nb, VUN100,
and VUN100bv) or monocytes pre-treated with 20 ng/ml PMA before infection (PMA) were co-cultured with Hff1 fibroblasts. IE-positive infectious foci
formation was quantified after 4 days of co-culturing. d Six days post infection, HCMV-infected CD14+ cells were left untreated (Untr) or were treated
with NT Nb, VUN100, VUN100bv, or 20 ng/ml PMA (PMA). IE-positive nuclei were counted 8 days post infection. e Eight days post infection, untreated
(Untr), nanobody-treated (NT Nb, VUN100, and VUN100bv) or PMA-treated monocytes were co-cultured with Hff1 fibroblasts. IE-positive infectious foci
were quantified after 8 days of co-culturing. Representative figures, showing technical replicates, from two (Fig. 2d, e) or four (Fig. 2a b) biological
replicates are shown. All data are plotted as mean ± S.D. For all figures, statistical analyses were performed using unpaired two-tailed t test. ns, p > 0.05.
Source data are provided as a Source Data file.
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CTLs. For this, CD14+ monocytes, CD4/CD8+ T cells, and T-
cell-depleted PBMCs were isolated from HCMV-positive donors.
Mindful of any potential non-specific nanobody effects, we con-
sidered a treatment of CD14+ monocytes with the non-targeting
nanobody to be the most adequate control in the analysis of the
results. Six days post infection and nanobody or PMA pre-
treatment, IE-positive cells were counted. As seen previously,
VUN100bv treatment and pre-treatment with PMA resulted in an
increase of IE2-eYFP-expressing cells (Fig. 4a). After these 6 days,
the infected CD14+ monocytes were further split into two groups
for subsequent co-culturing with either T cells or T-cell-depleted
PBMCs. After 48 h of co-culturing, T cells were removed and any
remaining latently infected CD14+ monocytes were treated with
GM-CSF/IL-4 and LPS, which is known to differentiate mono-
cytes into functionally mDCs, a biologically relevant cell type that
is known to reactivate HCMV from natural latency21 (Fig. 4b).
Interestingly, almost no IE-positive mDCs were observed upon
treatment with either VUN100bv or PMA in combination with
T-cell co-culturing. This was not seen after co-culturing with T-
cell-depleted PBMCs, indicating a pivotal role for T cells for the
removal of reactivated cells. In contrast, treatment with the non-
targeting nanobody did not result in a significant T-cell-mediated
decrease in IE-positive mDCs. In addition, we also assessed
whether VUN100bv treatment of HCMV-infected cells also
resulted in T-cell-mediated clearance after the establishment of
latency. Six days post infection (and before nanobody treatment),
cells were divided into two groups for nanobody treatment.
Before the addition of nanobodies, no difference in IE2-eYFP-
expressing cells between the different groups was observed
(Supplementary Fig. 8). Next, cells were treated with non-
targeting nanobody, VUN100bv, or PMA. One day post treat-
ment, a significant increase of IE2-eYFP-expressing cells was seen
upon VUN100bv and PMA treatment (Fig. 4c). The infected
CD14+ monocytes were again co-cultured with either T cells or
T-cell-depleted PBMCs for 48 h after which T cells were removed
and CD14+ monocytes were differentiated into mature dendritic
cells to give cellular conditions conducive to viral reactivation
(Fig. 4d). Two days post co-culturing of T cells with PMA-treated
CD14+ monocytes resulted in a significant decrease of IE-positive
CD14+ monocytes compared with co-culturing with T-cell-
depleted PBMCs. Again, the non-targeting nanobody did not
affect the number of IE-expressing cells significantly when co-
cultured with either T cells or the T-cell-depleted PBMCs.
Although these data nicely illustrate the potential of the
VUN100bv nanobody, one drawback of the HCMV IE2-eYFP
virus used in the analysis is that it contains a deletion of the virus
US2-US6 region. This region encodes several proteins that
interfere with antigen presentation by, for example, down-
regulating MHC Class I and II molecules22–24. Though it should
be pointed out, that this HCMV IE2-eYFP virus does encode
US11 (as shown by RT-qPCR, Fig. 3d), which can downregulate
some MHC Class I molecules25,26. However, to ensure that our
observations would also be recapitulated with a virus with a full
complement of immune evasins, we repeated the co-culture
experiments described above with the HCMV strain containing
an intact US2-6 region27, here termed HCMV-US2-6. CD14+
monocytes from HCMV-positive donors were infected with
HCMV-US2-6 and treated with nanobody or PMA, or left
untreated. After 6 days of treatment, we determined HCMV
genome (g)DNA copy numbers to assess the effect of treatments
on viral reactivation (Fig. 5a). Consistent with both our co-
culturing experiments of HCMV IE2-eYFP infected CD14+
monocytes with fibroblasts (Figs. 2c, e) and transcript data
(Fig. 3), we observed no increase in HCMV gDNA copy numbers
upon VUN100bv treatment compared to the untreated or non-
targeting nanobody-treated HCMV-infected CD14+ monocytes








































































































Fig. 3 VUN100bv increases immediate-early, early and late gene but no true late gene expression. CD14+ monocytes were left uninfected (Uninf) or
infected with HCMV IE2-eYFP. Infected monocytes were left untreated (Untr), treated with a non-targeting nanobody (NT Nb), VUN100, VUN100bv, or
pre-treated with 20 ng/ml PMA before infection (PMA). Six days post infection, RNA was isolated and IE72 (a), UL44 (b), UL32 (c), and US11 (d) gene
expression was measured by RT-qPCR. Representative figures, showing technical replicates, from two biological replicates are shown. All data are plotted
as mean ± S.D. For all figures, statistical analyses were performed using unpaired one-way ANOVA with Tukey’s multiple comparison test. ns, p > 0.05.
Source data are provided as a Source Data file.
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showing that VUN100bv treatment indeed did not result in the
viral DNA replication. In contrast, PMA treatment resulted in a
significant increase of HCMV gDNA copy numbers (indicating
extensive viral replication). Next, untreated or nanobody-treated
HCMV-US2-6 infected CD14+ monocytes were co-cultured with
autologous T cells for 2 days. After the removal of the T cells,
HCMV gDNA copy numbers were determined prior to and after
differentiation to mDCs and co-culturing with fibroblasts for
8 days to assess the reactivation potential of remaining latently
infected CD14+ monocytes (Fig. 5b). We saw a clear increase in
HCMV gDNA copy numbers for both the untreated and non-
targeting nanobody-treated infected CD14+ monocytes, indicat-
ing reactivation of HCMV. In contrast, no increase of HCMV
gDNA copy numbers was observed after VUN100bv treatment,
consistent with loss of the latent cell pool. Overall, these data
indicate that partial reactivation of latently infected cells by
VUN100bv is sufficient to induce IE expression to levels that
allow HCMV-specific T-cell-mediated clearing of latently infected
monocytes.
Discussion
HCMV establishes a latent infection in CD34+ progenitor cells
and CD14+ monocytes28,29. Although only present in a small
percentage of these cells, reactivation of HCMV can lead to dis-
ease or mortality in immunosuppressed transplant patients and
immunocompromised individuals30,31. Importantly, no current
antiviral agents target this latent reservoir, leaving an unmet need
to target these latently infected cells. In this study, we set out to
target the HCMV-encoded chemokine receptor US28 using a
newly developed bivalent US28 nanobody to partially reactivate
HCMV latently infected cells and drive their T-cell recognition
and killing.
We used the previously described US28-targeting nanobody
VUN100 to develop a new bivalent format VUN100bv14. Inter-
estingly, the coupling of two antagonistic monovalent VUN100
nanobodies resulted in a bivalent format with partial inverse
agonistic properties. Although the mechanism behind this still
has yet to be explained, similar observations were made with



























































































































Fig. 4 HCMV-infected CD14+ monocytes are targets for HCMV-specific T cells upon VUN100bv treatment. a Counting of IE-positive CD14+ monocytes
before co-culture with CD4/CD8+ T cells or T-cell-depleted PBMCs. CD14+ monocytes were treated with a non-targeting nanobody (NT Nb), VUN100bv
for 6 days post infection or pre-treated with 20 ng/ml PMA before infection. b Counting of IE-positive CD14+ monocytes after co-culture of T-cell-depleted
PBMCs (depleted PBMC) or T cells (CD4/CD8) and differentiation of CD14+ monocytes to mature dendritic cells. c Counting of IE-positive CD14+
monocytes before co-culture with CD4/CD8+ T cells or T-cell-depleted PBMCs. Six days post infection, CD14+ monocytes were treated with NT Nb,
VUN100bv, or 20 ng/ml PMA for 1 day. d Counting of IE-positive CD14+ monocytes after co-culture of T-cell-depleted PBMCs (depleted PBMC) or T cells
(CD4/CD8) and differentiation of CD14+ monocytes to mature dendritic cells. Representative figures, showing technical replicates, from two biological
replicates are shown. All data are plotted as mean ± S.D. For all figures, statistical analyses were performed using unpaired two-tailed t test. ns, p > 0.05.
Source data are provided as a Source Data file.
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could bind and partially inhibit US28 signaling in cultured cell
lines, and we recapitulated our observations in experimental
latency settings in primary CD14+ monocytes. Here, we saw
upregulation of IE gene expression without substantial immune
evasin gene expression, late gene expression, viral DNA replica-
tion, or full virus reactivation. This is a major advantage for a
shock-and-kill strategy, which requires detection by host
immunity6,35. On a molecular level, our findings suggest that
there is a threshold of inhibition of US28 signaling required for
full viral reactivation.
Interestingly, the monovalent nanobody VUN100 was able to
partially restore IFI16 levels in THP-1 cells and also induced
some IE gene expression in CD14+ monocytes of most donors
despite not inhibiting US28 constitutive signaling. VUN100
blocks ligand binding, and the ligand-binding activity of US28
has been shown to be required for the establishment in some, but
not all, experimental latency systems11,12,14,36. Furthermore, the
donor-to-donor variability we observed in the VUN100 effect
raises questions about the role of US28 ligand binding during
HCMV latency in patients. In contrast, VUN100bv consistently
and robustly induced IE expression in all donors tested and led to
recognition and killing by CTLs from seropositive individuals.
Moreover, we were able to validate these results upon establish-
ment of latency ensuring that VUN100bv not only hampers
latency establishment but also induces partial reactivation of
latently infected cells. Because our results were obtained using
experimentally latently infected cells, follow-up experiments
using ex vivo PBMCs from naturally infected donors would
provide valuable confirmation of the current results. Nevertheless,
our current studies are consistent with previous reports of shock-
and-kill strategies using epigenetic modifiers, such as HDAC
inhibitors, to induce transient viral gene expression7,37–39.
However, treatment with HDAC inhibitors is associated with
substantial off-target effects due to other and more physiological
functions of these enzymes40. In contrast to such inhibitors, we
have, here, developed a molecule specific to HCMV-infected cells
and, therefore, it should display limited off-target effects.
Recently, the first FDA-approved nanobody has entered the clinic
for treatment of acquired Thrombotic Thrombocytopenic
Purpura41,42. This paves the way for the potential therapeutic use
of HCMV-specific nanobodies. In addition to their intrinsic
activity, the efficacy of such nanobodies in experimental and
clinical settings could be further enhanced through coupling to
effector molecules14,43–47.
Overall, our study provides a strong basis for using inverse
agonistic/inhibitory anti-US28 nanobodies to reduce latent viral
loads in transplant donors and/or recipients prior to surgery and
immunosuppression. This could lead to a lower incidence of
CMV-associated disease and mortality during life-saving solid
organ and stem cell transplantation.
Methods
Cell culture and virus infection. Primary CD14+ monocytes were isolated from
apheresis cones (NHS Blood and Transfusion Service, United Kingdom), using
Lymphoprep (STEMCELL Technologies, Vancouver, Canada) density gradient
centrifugation followed by magnetic-activated cell sorting (MACS) separation
using CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). The
monocytes were adhered to tissue culture dishes (Corning, Tewksbury, MA, USA)
and were cultured in X-vivo 15 (Lonza, Walkersville, MD, USA) supplemented
with 2 mM L-glutamine (Gibco, ThermoFisher Scientific, Waltham, MA, USA) at
37 °C in 5% CO2. PMA (Sigma-Aldrich, Saint-Louis, MO, USA) was used as
described in figure legends at 20 ng/mL to induce differentiation of monocytes to a
macrophage-like phenotype and is known to result in reactivation of HCMV lytic
infection within 24 h of treatment13. Primary CD14+ monocytes for use in T-cell
co-culturing experiments were isolated from peripheral blood of HCMV-positive
donors as for apheresis cones. CD4+ and CD8+ T cells from these HCMV-
seropositive donors were isolated by MACS from monocyte-depleted PBMC using
CD4 and CD8 microbeads (Miltenyi Biotec).
THP-1 cells (ATCC TIB-202), lentivirally transduced with different US28
constructs, have been described previously12 and were cultured according to ATCC
standards (RPMI-1640 media (Sigma-Aldrich)) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; PAN Biotech, Aidenbach, Germany), 100 U/
mL penicillin and 100 µg/mL streptomycin (Sigma-Aldrich), and 0.05 mM 2-
mercaptoethanol (Gibco) maintained at 37 °C in 5% CO2).
HEK293T cells (ATCC CRL-11268) were grown at 5% CO2 and 37 °C in
Dulbecco’s Modified Eagle’s Medium (DMEM, ThermoFisher Scientific)
supplemented with 1% Penicillin/Streptomycin (ThermoFisher Scientific) and 10%
FBS (ThermoFisher Scientific). These cells were used to generate HEK293T cells
overexpressing US28 and have been described previously48.
Human foreskin fibroblasts (Hff1; ATCC SCRC-1041) were maintained in
DMEM (Sigma-Aldrich) supplemented with 10% heat-inactivated FBS and 100 U/
mL penicillin and 100 µg/mL streptomycin.
Viral isolate RV1164 (HCMV TB40/E strain with an IE2-eYFP tag) has been
described previously49. Titan WT and ΔUS28 strains have been described
previously50. For experiments using HCMV containing an intact US2-6 region, we
used isolate TB40-UL32-GFP-HCMV, which has been described earlier27. CD14+























































Fig. 5 VUN100bv treatment drives a T-cell-mediated reduction of HCMV reactivation without driving viral DNA replication in latently infected cells. a
Quantification of HCMV gDNA copy numbers of uninfected (Uninf) or HCMV-US2-6 infected CD14+ monocytes before co-culture with CD4/CD8+
T cells. Infected monocytes were untreated (Untr), treated with a non-targeting nanobody (NT Nb), VUN100bv, or 20 ng/ml PMA (PMA) for 6 days. Total
genomic DNA was harvested and HCMV gDNA copy numbers were determined by quantifying GAPDH and UL44 gene numbers via qPCR. HCMV gDNA
copy numbers were normalized to the untreated infected wells. b Quantification of HCMV gDNA copy numbers of untreated NT Nb or VUN100bv treated
HCMV-US2-6 infected CD14+ monocytes after co-culturing with CD4/CD8+ T cells. HCMV gDNA copy numbers were determined prior to (Pre) and
after (Post) differentiation of CD14+ monocytes to mature dendritic cells and co-culturing with fibroblasts for 8 days. Total genomic DNA was harvested
and HCMV gDNA copy numbers were determined by quantifying GAPDH and UL44 gene numbers via qPCR. HCMV gDNA copy numbers were normalized
to the untreated wells prior to differentiation to mature dendritic cells. Representative figures, showing technical replicates, from three biological replicates
are shown. All data are plotted as mean ± S.D. For all figures, statistical analyses were performed using unpaired two-tailed t test. ns, p > 0.05. Source data
are provided as a Source Data file.
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monocytes were infected at a multiplicity of infection of 3 for 2 h, were washed
twice with phosphate-buffered saline (PBS), before replacing with fresh X-vivo 15
+ L-glutamine.
Nanobody production. Nanobody gene fragments were recloned in a frame with a
myc-His6 tag in the pET28a production vector. Bivalent formats of VUN100 were
constructed by the addition of a 30GS linker in frame with the nanobody frag-
ments. Transformed BL21+ E. coli were grown in an orbital shaker at 37 °C in
Terrific Broth containing 50 μg/mL kanamycin. When the culture reached an
OD600 of 0.5, nanobody production was induced by the addition of isopropyl-β-D-
thiogalactopyranoside (Sigma-Aldrich) to a final concentration of 1 mM. Incuba-
tion then continued at 37 °C for 3–4 h. Cultures were spun down for 30 min at
4000 RPM and the pellets were frozen overnight at −20 °C. The next day, pellets
were thawed and resuspended in PBS. The resuspended pellet was incubated at 4 °
C head-over-head at 20 RPM for 2 h. Cultures were spun down for 20 min at 4000
RPM at 4 °C and the nanobodies were purified from the supernatant using a 1 mL
HisTrap HP column (GE Healthcare, Chicago, Illinois, USA). The purity of the
nanobodies was verified by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) (Bio-Rad, Hercules, CA, USA).
Nanobody binding enzyme-linked immunosorbent assay (ELISA). Nanobody
binding was performed as described previously14. In brief, US28-expressing
membrane extracts were coated in a 96-well MicroWell MaxiSorp flat bottom plate
(Sigma-Aldrich) overnight at 4 °C. The next day, wells were washed and blocked
with 2% (w/v) skimmed milk (Sigma-Aldrich) in PBS. Different concentrations of
nanobodies were incubated. Nanobodies were detected with mouse-anti-Myc
antibody (1:1000, clone 9B11, Cell Signaling Technology, Leiden, The Netherlands)
and Goat anti-Mouse IgG-HRP conjugate (1:1000, #1706516, Bio-Rad). Optical
density was measured at 490 nm with a PowerWave plate reader (BioTek,
Winooski, VT, USA). Data were analyzed using GraphPad Prism version 8.0
(GraphPad Software, Inc., La Jolla, CA, USA).
Competition binding. Membrane extracts of HEK293T and HEK293T over-
expressing US28 were used during competition binding studies. Cells were washed
with cold PBS and resuspended afterward in cold PBS. The cell solution was pelleted
via centrifugation at 1500 × g at 4 °C. The cell pellet was washed with cold PBS and
spun down again. The pellet was resuspended in membrane buffer (15mM Tris-Cl,
0.3 mM EDTA, 2mM MgCl2, pH 7.5) and disrupted by the homogenizer Potter-
Elvehjem at 1200 rpm. Protein concentrations were determined using Pierce BCA
protein assay kit (ThermoFisher Scientific). Increasing amounts of nanobodies or
unlabeled CX3CL1 were added 100 pM 125I-CX3CL1in HEPES binding buffer (50
mM HEPES-HCl, pH 7.4; 1 mM CaCl2; 5 mM MgCl2; 0.1M NaCl; 0.5% (w/v)
bovine serum albumin). Radioligand alone and radioligand + 100 nM of unlabeled
CX3CL1 were used as controls for total binding and non-specific binding. A total of
3 µg of HEK293T or HEK293T overexpressing US28 were added to the ligands and
incubated for 2 h at room temperature. Membranes were harvested on 0.5%(w/v)
polyethylenimine (PEI)-soaked GF/C filter plates (Perkin-Elmer, Waltham, MA,
USA) and dried for 30min at 60 °C. In addition, 100 pM of 125I-CX3CL1 was
spotted on the GF/C filter plate to determine radioligand concentration. Scintillation
fluid MicroScint-O (Perkin-Elmer) was added to the GF/C filter plate and radio-
active decay was measured using a Microbeta liquid scintillation counter (Perkin-
Elmer). Data were analyzed using GraphPad Prism version 8.0.
NFAT reporter gene assay. HEK293T cells were detached using Trypsin-EDTA
0.05% (Gibco). In all, 1 × 106 cells were transfected with a total of 2 μg DNA and
12 μg 25 kDa linear PEI (Sigma-Aldrich) in 150 mM NaCl solution. For the
transfection, 20 ng of pcDEF3-HA-US28 VHL/E WT/Y16F/R129A or 200 ng HA-
US28 pcDEF3-HA-US28 ΔN(2–22) and 1 μg of NFAT-luciferase reporter gene
(Stratagene, La Jolla, CA, USA) was used, which was supplemented with pcDEF3
empty DNA to a total of 2 μg. The DNA-PEI mixture was vortexed for 3 s and
incubated for 15 mins at room temperature and resuspended in DMEM. The
HEK293T cell suspension was added to DNA-PEI mixture and 30,000 cells per well
were seeded in a white poly-L-lysine coated 96-wells plate. Six hours post-trans-
fection, nanobodies were added with a final concentration of 100 nM or 1 µM, and
cells were incubated at 37 °C and 5% CO2. After 24 h, supernatant was removed
and 25 μL LAR (0.83 mM D-luciferine, 0.83 mM ATP, 0.78 μM Na2HPO4, 18.7 mM
MgCl2, 38.9 mM Tris-HCl (pH 7.8), 2.6 μM DTT, 0.03% Triton X-100 and 0.39%
Glycerol) was added. Luminescence (3 s per well) was measured using a VICTOR3
multilabel plate reader (Perkin-Elmer). Raw data were normalized to the average
signal of the wells containing untreated US28 WT cells. Data were analyzed using
GraphPad Prism version 8.0.
US28 receptor expression ELISA. Transiently transfected cells, used for NFAT
reporter assay, were seeded at 50,000 cells per well in poly-L-lysine coated 96-well
plates and were grown at 37 °C and 5% CO2. The next day, cells were fixed with 4%
paraformaldehyde (Sigma-Aldrich) for 10 min at room temperature. Cells were
permeabilized with 0.5% NP-40 (Sigma-Aldrich) for 30 min at room temperature
and subsequently blocked for 30 min at room temperature in 1% (v/v) FBS/PBS.
Cells were incubated with the rat-anti-HA antibody (1:1000, Clone 3F10, Roche,
Basel, Switzerland) for 1 h at room temperature. Subsequently, cells were incubated
with Goat anti-Rat IgG-HRP conjugate (1:1000, Pierce, Thermo Scientific) for 1 h
at room temperature. Between all incubation steps, cells were washed three times
with PBS. 1-Step Turbo TMB-ELISA substrate (Thermo Scientific) was added to
the wells and the reaction was stopped with 1M H2SO4. Optical density was
measured at 450 nm with a PowerWave plate reader. Data were analyzed using
GraphPad Prism version 8.0.
Immunofluorescence microscopy. THP-1 cells were spun down at 500 × g for 5
min, resuspended in 4% paraformaldehyde (Sigma-Aldrich), and seeded in a 96-
well U-bottom plate. Cells were fixed for 10 mins at room temperature. After
fixation, cells were permeabilized with 0.5% NP-40 (Sigma-Aldrich) for 30 min at
room temperature. Nanobodies were incubated for 1 h at RT and detected using
Mouse-anti-Myc antibody (1:1000, 9B11 clone, Cell Signaling). US28 was visua-
lized with the rabbit-anti-US28 antibody (1:1000, Covance, Denver, PA, USA51) for
1 h at room temperature. Subsequently, cells were washed and incubated with Goat
anti-Rabbit Alexa Fluor 546 (1:1000 in 1% (v/v) FBS /PBS, ThermoFisher Scien-
tific) and Goat anti-Mouse Alexa Fluor 488 (1:1000 in 1% (v/v) FBS/PBS, Ther-
moFisher Scientific).
IE antigen was detected in monocytes and fibroblasts by fixation and
permeabilization in 70% ethanol at −20 °C for 30 mins and blocking using PBS
with 1 % bovine serum albumin and 5% goat serum, and then incubating with
mouse-anti-IE antibody (1:1000, #11-003, Argene, bioMériux, Marcy-l’étoile,
France) followed by secondary antibodies as described above.
Western blot. Mock transduced or US28-expressing THP-1 cells were seeded in a
six wells plate and incubated with 100 nM nanobodies. After 48 h, cells were lysed
in native lysis buffer (25 mM Tris-HCL pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
NP-40, 5% Glycerol, 1 mM NaF, 1 mM NaVO3, cOmplete protease inhibitor
cocktail) for 10 min on ice. Cell debris was removed by centrifugation at 13,000 × g.
Protein concentration of lysates was determined by Pierce BCA protein assay kit
(ThermoFisher Scientific) and the same protein quantities were separated on a 10%
SDS-PAGE gel under reducing conditions and transferred to 0.45 μm poly-
vinylidene fluoride blotting membrane (GE healthcare, Chicago, IL, USA). Total
ERK1/2 and phospho-ERK1/2 were detected using p44/42 MAPK antibody (1:1000
in 5% BSA/TBS-T, #9102, Cell Signaling) and phospho-p44/42 MAPK (Thr202/
Tyr204) (1:1000 in 5% BSA/TBS-T, #9106, Cell Signaling). Total IFI16 was detected
using anti-IFI16 antibody (1:500 in 5% BSA/TBS-T, sc-8023, Santa Cruz). Actin
was detected using anti-actin antibody (1:2000 in 5% BSA/TBS-T, Clone AC-74,
Sigma-Aldrich). Antibodies were detected using Goat anti-Rabbit IgG-HRP con-
jugate (1:10000, #1706515, Bio-Rad) or Goat anti-Mouse IgG-HRP conjugate
(1:10000, #1706516, Bio-Rad). Blots were developed using Western Lightning Plus-
ECL (Perkin-Elmer) and visualized with Chemidoc (Bio-Rad).
Detection of IE expression and IE focus formation. CD14+ monocytes were
isolated and seeded in a 96-well plate. In some experiments, as a positive control,
CD14+ monocytes were pre-treated with 20 ng/ml PMA 1 day after seeding. The
next day, the medium was removed and cells were infected with RV1164 viral
isolate. Two hours post infection, the medium was aspirated and replaced with
medium containing nanobodies at a final concentration of 100 nM. Three days post
infection, nanobody-containing medium was refreshed. Six days post infection, IE
expression was detected by means of IE2-eYFP tag or staining of IE as described
above. These were either counted manually or using the Target Activation
experimental tool of the ArrayScan XTI instrument (ThermoFisher), using Hoechst
stained nuclei for object identification.
During the prolonged protocol, to allow the establishment of latency, CD14+
monocytes were isolated and seeded in a 96-wells plate. The next day, the medium
was removed and cells were infected with RV1164, Titan WT, or Titan ΔUS28 viral
isolate. Two hours post infection, the medium was aspirated and media was
replaced with fresh X-vivo 15+ L-glutamine. Six days post infection, IE-expressing
cells were counted. Next, the medium was aspirated and replaced with medium
containing nanobodies at a final concentration of 100 nM of PMA at a final
concentration of 20 ng/ml. IE expression was determined two days after the
addition of nanobodies or PMA. Next, Hff1 cells were detached using Trypsin-
EDTA 0.05% (Gibco). The medium of the wells containing CD14+ monocytes was
removed and 10,000 Hff1 cells were co-cultured with the CD14+ monocytes to
determine the production of infectious viral particles. IE focus formation was
monitored for up to 14 days.
RNA extraction and analysis. CD14+ monocytes were isolated and infected as
described above. Six days post infection, cells were washed once with 1× PBS, and
RNA was harvested by adding Trizol reagent (Zymo Research, Irvine, CA, USA).
RNA was isolated using Direct-Zol RNA MiniPrep kit (Zymo Research) according
to the manufacturer’s instructions. cDNA was produced by Quantitect Reverse
Transcription kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions.
qPCR was performed using LUNA SYBR green qPCR reagents (New England
Biolabs, Ipswich, MA, USA) using primers presented in Supplementary Table 2.
Viral transcript levels were normalized to GAPDH and are presented as 2ΔCt.
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PBMC and T-cell co-culture and virus reactivation. For experimental latency
experiments, following PBMC isolation from an HCMV-positive healthy donor
peripheral blood, CD14+ monocytes were isolated, plated on 96-well plates, and
treated as described above and in the figure legends, and the remaining PBMC were
frozen in liquid nitrogen until one day prior to co-culture. At this time, the PBMC
were thawed and rested overnight. CD4+ and CD8+ T-cell fractions were isolated
as above and pooled, and these, or the remaining PBMC were added to the
monocyte cultures at an effector:target cell ratio of 5:1. After 2 days, the T cells/
depleted PBMC were washed away using PBS+ 2 mM EDTA, and the medium on
the monocytes was replenished with X-vivo 15+ L-glutamine containing
interleukin-4 (Miltenyi Biotec) and granulocyte-macrophage colony-stimulating
factor (Miltenyi Biotec) at 1,000 U/ml in order to stimulate differentiation to
immature dendritic cells, along with 10 μg/mL anti-HLA-A, B, C (Biolegend)
and 10 μg/mL anti-HLA-DR, DP, DQ (BD Bioscience) to block any further T-cell
killing. After 5 days, this medium was aspirated and replaced with X-vivo 15+ L-
glutamine supplemented with 50 ng/mL LPS (Invivogen, San Diego, CA, USA)
for 2 days to induce maturation of dendritic cells, a biologically relevant cell
type which is known to reactivate HCMV from natural latency21. This media
was aspirated and 1 × 104 Hff1 cells were added to each well in DMEM-10
medium. IE focus formation was determined during a period of 10 days of
co-culturing.
Detection of HCMV genomic DNA in latent and reactivated CD14+ mono-
cytes. CD14+ monocytes were isolated from an HCMV-seropositive individual
and seeded in a 48-well plate. The next day, the medium was removed and cells
were infected with the HCMV-US2-6 (TB40-UL32-GFP) viral isolate. Two hours
post infection, the medium was aspirated and replaced with medium containing
nanobodies at a final concentration of 100 nM, or PMA at 20 ng/mL. Three days
post infection, nanobody-containing medium was refreshed. Six days post infec-
tion, ~1/3 of the wells were harvested for DNA extraction (described below). The
remaining wells were treated with CD4/CD8+ T cells in the presence of nanobodies
for two days before removal as described above. Approximately 1/3 of the wells
were harvested for DNA extraction and the remaining wells were treated with X-
vivo 15+ L-glutamine medium containing interleukin-4 (Miltenyi Biotec) and
granulocyte-macrophage colony-stimulating factor (Miltenyi Biotec) at 1,000 U/ml
in order to stimulate differentiation to immature dendritic cells, along with 10 μg/
mL anti-HLA-A, B, C (Biolegend) and 10 μg/mL anti-HLA-DR, DP, DQ (BD
Bioscience) to block any further T-cell killing. After 5 days, this medium was
aspirated and replaced with X-vivo 15+ L-glutamine supplemented with 50 ng/mL
LPS (Invivogen, San Diego, CA, USA) for 2 days to induce maturation of dendritic
cells. This media was aspirated and 3 × 104 Hff1 cells were added to each well in
DMEM-10 medium. After 7–8 days, these wells were harvested for DNA extraction
as follows.
For analysis of viral genomes, cells were washed with PBS, then solution A (100
mM KCl, 10 mM Tris-HCl pH8.3 2.5 mM MgCl) was added followed by an equal
volume of solution B (10 mM Tris-HCl pH8.3, 2.5 mMMgCl 1% Tween20, 1% NP-
40, 0.4 mg/ml proteinase K). Cells were scraped and placed in microtubes before
heating at 60 °C for 1 h then 95 °C for 10 mins. Two μl of each solution was used in
qPCR analysis of the UL44 non-transcribed promoter region, using the GAPDH
non-transcribed promoter region to correct for total DNA levels. Primer sequences
are provided in the table.
Ethical approval for the use of human samples. Human samples were obtained
under ethical approval from Cambridgeshire 2 Research Ethics Committee
(REC reference 97/092) conducted in accordance with the Declaration of Helsinki.
All volunteers have given informed written consent before providing blood
samples.
Statistical analysis. For the validation of the nanobody, each experiment is
consisting of two to four technical replicates of three or four biological replicates.
For the virus experiments, three to six technical replicates of one to four different
donors have been used. No outliers were removed from the experiments. Data were
analyzed using GraphPad Prism version 8.0 software. All figures are representative
figures and all data are plotted as mean ± S.D. Statistical analyses were performed
using unpaired two-tailed t test, one-way ANOVA with Tukey’s multiple com-
parison tests, two-way ANOVA with Tukey’s multiple comparison test, or the
Holm–Sidak method with alpha = 0.05 and are mentioned in the figure legends. P
value < 0.05 was considered statistically significant.
Biological material availability. US28-targeting nanobodies, described in this
paper, can be obtained through an MTA. The HCMV strains RV1164 (TB40-IE2-
eYFP-HCMV), Titan WT, Titan ΔUS28, and TB40-UL32-GFP-HCMV are all
published and not ours to make available.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data associated with this study are present in the paper or in the Supplementary
Information file. The data that support the findings of this study are available from the
corresponding author upon reasonable request. Source data are provided with this paper.
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